JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Ki-67/MIB-1 as a Prognostic Marker in Cervical Cancer - a Systematic Review with Meta-Analysis
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Ki-67/MIB-1 as a Prognostic Marker in Cervical Cancer - a Systematic Review with Meta-Analysis
Piri, Reza; Ghaffari, Alireza; Gholami, Nasrin; Azami-Aghdash, Saber; PourAli-Akbar, Yasmin; Saleh, Parviz; Naghavi-Behzad, Mohammad;
  PDF(new window)
 Abstract
Background: In cervical cancer patients it has been reported that there in a significant Ki-67/MIB-1 expression is correlated with survival in cervical cancer patients. However, the prognostic value is still not well understood. Materials and Methods: In the present meta-analysis the prognostic value of Ki-67/MIB-1 with regard to overall survival (OS) and disease-free survival (DFS) in cervical cancer was investigated. The databases of PubMed, ISI Web of Science, Cochrane Central Register of Controlled Trials, EMBASE, Science Direct and Wiley Online Library were used to identify appropriate literature. Results: In order to explore the relationship between Ki-67/MIB-1 and cervical cancer, we have included 13 studies covering 894 patients in the current meta-analysis. The effect of Ki-67/MIB-1 on OS for pooled random effects HR estimate was 1.63 (95%confidence interval (CI) 1.09-2.45; P<0.05). The pooled HR for DFS was 1.26 (95%CI 0.58-2.73; P>0.05) and the subgroup analysis indicated Ki-67/MIB1 was associated with DFS (HR
 Keywords
Cervical cancer;Ki-67/MIB-1;prognosis;meta-analysis;
 Language
English
 Cited by
 References
1.
Aliasgarzadeh A, Ghojazadeh M, Haji-Hoseini R, et al (2014). Age related secretary pattern of growth hormone, insulinlike growth factor-I & insulin-like growth factor binding protein-3 in postmenopausal women. Indian J Med Res, 139, 598-602.

2.
Altman DG, Lausen B, Sauerbrei W, et al (1994). Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst, 86, 829-35. crossref(new window)

3.
Amirnia M, Babaie-Ghazani A, Fakhrjou A, et al (2014). Immunohistochemical study of cyclooxygenase-2 in skin tumors. J Dermatolog Treat, 25, 380-7. crossref(new window)

4.
Andrae B, Andersson TM, Lambert PC, et al (2012). Screening and cervical cancer cure: population based cohort study. Bmj, 344.

5.
Azami-Aghdash S, Ghaffari S, Sadeghi-Bazargani H, et al (2013). Developing Indicators of Service Quality Provided for CardiovascularPatients Hospitalized in Cardiac Care Unit. J Cardiovascular Thoracic Res, 5, 23.

6.
Azami-Aghdash S, Ghojazadeh M, Pournaghi Azar F, et al (2013). Fluoride concentration of drinking waters and prevalence of fluorosis in iran: a systematic review. J Dent Res Dent Clin Dent Prospects, 7, 1-7.

7.
Bahnassy AA, Zekri AR, Alam El-Din HM, et al (2006). The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egypt Natl Canc Inst, 18, 292-302.

8.
Bahnassy AA, Zekri AR, Saleh M, et al (2007). The possible role of cell cycle regulators in multistep process of HPVassociated cervical carcinoma. BMC Clin Pathol, 7, 4. crossref(new window)

9.
Battista MJ, Mantai N, Sicking I, et al (2014). Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. Oncol Reports, 31, 2213-9.

10.
Chaturvedi AK, Engels EA, Pfeiffer RM, et al (2011). Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol, 29, 4294-301. crossref(new window)

11.
Costa S, Terzano P, Santini D, et al (2001). Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol, 116, 729-37. crossref(new window)

12.
Cserni G, Voros A, Liepniece-Karele I, et al (2014). Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast, 23, 259-63. crossref(new window)

13.
de Azambuja E, Cardoso F, de Castro G, Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. crossref(new window)

14.
Eskander RN, Tewari KS (2014). Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol, 25, 249-59. crossref(new window)

15.
Fakhrjou A, Dastranj-Tabrizi A, Ghojazadeh M, et al (2013). Diagnostic value of protein Ki67 (MIB-1) in atypical pap smears of postmenopausal women. Asian Pac J Cancer Prev, 14, 4815-8. crossref(new window)

16.
Fasanella S, Leonardi E, Cantaloni C, et al (2011). Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol, 6, 7. crossref(new window)

17.
Ghojazadeh M, Azar ZF, Saleh P, et al (2012a). Knowledge and attitude of Iranian university students toward human papilloma virus. Asian Pac J Cancer Prev, 13, 6115-9. crossref(new window)

18.
Ghojazadeh M, Mohammadi M, Azami-Aghdash S, et al (2013). Estimation of cancer cases using capture-recapture method in Northwest Iran. Asian Pac J Cancer Prev, 14, 3237-41. crossref(new window)

19.
Ghojazadeh M, Naghavi-Behzad M, Azar ZF, et al (2012b). Parental knowledge and attitudes about human papilloma virus in Iran. Asian Pac J Cancer Prev, 13, 6169-73. crossref(new window)

20.
Ghojazadeh M, Naghavi-Behzad M, Nasrolah-Zadeh R, et al (2014). Knowledge production status of Iranian researchers in the gastric cancer area: based on the medline database. Asian Pac J Cancer Prev, 15, 5083-8. crossref(new window)

21.
Goldhirsch A, Winer E, Coates A, et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 24, 2206-23. crossref(new window)

22.
Graflund M, Sorbe B, Karlsson M (2002). MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. Int J Oncol, 20, 1041-7.

23.
Ho DM, Hsu CY, Chiang H (2000). MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol, 76, 97-102. crossref(new window)

24.
Hu Y, Correa AM, Hoque A, et al (2011). Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer, 128, 132-43. crossref(new window)

25.
Ikenberg H, Bergeron C, Schmidt D, et al (2013). Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst, 105, 1550-7. crossref(new window)

26.
Jabbari H, Alikhah H, Alamdari NS, et al (2012). Developing the use of quality indicators in sterilization practices. Iranian J Health, 41, 64.

27.
Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca Cancer J Clin, 61, 69-90. crossref(new window)

28.
Karami H, Baradaran B, Esfahani A, et al (2013). siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev, 14, 7719-24. crossref(new window)

29.
Keam B, Im S-A, Lee K-H, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22.

30.
Kesic V, Poljak M, Rogovskaya S (2012). Cervical cancer burden and prevention activities in Europe. Cancer Epidemiol Biomarkers Prev, 21, 1423-33. crossref(new window)

31.
Klimek M, Kruczak A, Rys J, et al (2011). Clinico-morphological parameters affecting survival of patients with advanced cervical cancer. Pol J Pathol, 62, 250-6.

32.
Lindboe CF, Torp SH (2002). Comparison of Ki-67 equivalent antibodies. J Clin Pathol, 55, 467-71. crossref(new window)

33.
Lindboe CF, von der Ohe G, Torp SH (2003). Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies. APMIS, 111, 567-70. crossref(new window)

34.
Mohammadzadeh M, Pourzand A, Eftekhar-Sadat AT, et al (2013). A case of concurrent several forms of thyroid cancer. Niger Med J, 54, 351-3. crossref(new window)

35.
Naghavi-Behzad M, Alizadeh M, Azami S, et al (2013). Risk Factors of Congenital Heart Diseases: Case-Control Study in Northwest Iran. J Cardiovascular Thoracic Rese, 5, 5.

36.
Oka K, Suzuki Y, Nakano T (2000). High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma. Cancer, 89, 1526-31. crossref(new window)

37.
Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. crossref(new window)

38.
Peng Y, Wang L, Gu J (2013). Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg, 37, 208-13. crossref(new window)

39.
Rahimi-Ardabili B, Argani H, Ghorbanihaghjo A, et al (2012). Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. Renal Failure, 34, 1123-8. crossref(new window)

40.
Rostamizadeh L, Fakhrjou A, Montazeri V, et al (2013). Bcl-2 gene expression in human breast cancers in iran. Asian Pac J Cancer Prev, 14, 4209-14. crossref(new window)

41.
Shams-Vahdati S, Vand-Rajavpour Z, Paknezhad S-P, et al (2014). Cost-effectiveness of cardiac biomarkers as screening test in acute chest pain. J Cardiovasc Thoracic Res, 6, 29.

42.
Shiohara S, Shiozawa T, Miyamoto T, et al (2005). Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch, 446, 626-33. crossref(new window)

43.
Smith SJ, Tilly H, Ward JH, et al (2012). CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol, 124, 99-110. crossref(new window)

44.
Spyratos F, Ferrero-Pous M, Trassard M, et al (2002). Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer, 94, 2151-9. crossref(new window)

45.
Sugino T, Baba K, Hoshi N, et al (2011). Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Med Mol Morphol, 44, 146-50. crossref(new window)

46.
Sultana H, Kigawa J, Kanamori Y, et al (2003). Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol, 14, 214-9. crossref(new window)

47.
Sushma M, Vamsikrishna B, Babu M, et al (2014). A review on role of human papilomma virus (HPV) in cervical cancer. PharmaTutor, 2, 21-30.

48.
Suzuki M, Tsukagoshi S, Saga Y, et al (2000). Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer. Gynecol Oncol, 79, 300-4. crossref(new window)

49.
Tollefson MK, Karnes RJ, Kwon ED, et al (2014). Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the mayo model. Mayo Clinic Proc, 89, 308-18. crossref(new window)

50.
Van de Putte G, Kristensen GB, Lie AK, et al (2004). Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol, 92, 40-6. crossref(new window)

51.
Walts AE, Ines D, Marchevsky AM (2012). Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol, 25, 1258-64. crossref(new window)

52.
Wang M-J, Pei D-S, Qian G-W, et al (2011). p53 regulates Ki-67 promoter activity through p53-and Sp1-dependent manner in HeLa cells. Tumor Biol, 32, 905-12. crossref(new window)

53.
Warth A, Cortis J, Soltermann A, et al (2014). Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer, 111, 1222-9. crossref(new window)

54.
Yaghoubi A, Tabrizi JS, Mirinazhad MM, et al (2012). Quality of life in cardiovascular patients in Iran and factors affecting it: A systematic review. J Cardiovascular Thoracic Res, 4, 95.

55.
Yang M, Liu YD, Wang YY, et al (2014). Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol, 35, 929-34. crossref(new window)

56.
Yusuf S, Peto R, Lewis J, et al (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 27, 335-71. crossref(new window)

57.
Zhang T, Zhao C, Chen D, et al (2012a). Overexpression of AQP5 in cervical cancer: correlation with clinicopathological features and prognosis. Med Oncol, 29, 1998-2004. crossref(new window)

58.
Zhang T, Zhao C, Luo L, et al (2012b). The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol, 29, 1985-91. crossref(new window)